MedTrace Logo

Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02

NCT00659373 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2016-07-25

Study results available
· View outcomes & findings →

Summary

RATIONALE: Learning about the long-term effects of adjuvant tamoxifen (T), adjuvant tamoxifen with ovarian function suppression (T+OFS), and exemestane with ovarian function suppression (E+ OFS) on brain function may help doctors plan cancer treatment.

PURPOSE: This study is looking at brain function in premenopausal women who are receiving adjuvant tamoxifen (T) alone against those receive adjuvant tamoxifen (T+OFS) or exemestane (E+OFS) with ovarian function suppression (OFS) for early-stage breast cancer on clinical trial IBCSG-2402.

Conditions

Interventions

DRUG

Tamoxifen

DRUG

triptorelin

DRUG

Exemestane

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Breast Cancer Trials, Australia and New Zealand

    collaborator OTHER

  • Cancer and Leukemia Group B

    collaborator NETWORK

  • ETOP IBCSG Partners Foundation

    lead NETWORK

Principal Investigators

  • Juerg Bernhard, PhD · ETOP IBCSG Partners Foundation

  • Kelly-Anne Phillips · Peter MacCallum Cancer Centre, Australia

  • Timothy Ahles, MD · Cancer and Leukemia Group B

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
120 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2014-12-31
Completion
2016-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00659373 on ClinicalTrials.gov